Pfizer, sangamo therapeutics and gene

Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future of gene therapies.
Pfizer cuts losses on near-approval hemophilia gene therapy, adding to troubled Sangamo's woes
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones.
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade. Sangamo added that it has now regained the rights to the therapy's development and would explore all options to advance the program,
Pfizer kills hemophilia gene therapy deal, imperiling Sangamo
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE).
Pfizer Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
FiercePharma7h
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: report
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
BioPharma Dive5h
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Pfizer's 2025 Comeback: What's Driving Growth
Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Pfizer, Atavistik to collaborate on allosteric drug discovery
Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...